394 related articles for article (PubMed ID: 34620163)
1. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
[TBL] [Abstract][Full Text] [Related]
2. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
3. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
[TBL] [Abstract][Full Text] [Related]
4. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
5. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
7. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer.
Zhao L; Chen X; Wu H; He Q; Ding L; Yang B
Biochem Pharmacol; 2023 Sep; 215():115724. PubMed ID: 37524205
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
Zhang N; Gao Y; Huang Z; Dai P; Luo Y; Wu Q; Jiang X; Sun W; Zhang J; Han L; Zhang J; Gong Y; Xie C
Cancer Lett; 2022 Oct; 545():215852. PubMed ID: 35926817
[TBL] [Abstract][Full Text] [Related]
15. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
Lee EK; Konstantinopoulos PA
Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
Front Immunol; 2021; 12():762989. PubMed ID: 34975854
[TBL] [Abstract][Full Text] [Related]
17. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Gabrail N; Smith C
Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394
[TBL] [Abstract][Full Text] [Related]
18. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
19. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]